NEUROLOGICAL MANIFESTATIONS
OF CELIAC DISEASE

José Ibiapina Siqueira Neto¹, Ana Carolina Leite Vieira Costa², Francisco George Magalhães³, Gisele Sampaio Silva⁴

ABSTRACT - Celiac disease (CD/ Nontropicalsprue, gluten-sensitive enteropathy) is a malabsortive condition in which an allergic reaction to the cereal grain-protein gluten (present in wheat, rye and barley) causes small intestine mucosal injury. The onset is in the first four decades of life, with a female to male ratio of 2:1. It may be associated with a wide spectrum of neurological manifestations including cerebellar ataxia, epileptic seizures, dementia, neuropathy, myopathy and multifocal leucoencephalopathy. We report three patients with neurological manifestations related with CD: one with cerebellar ataxia, one with epilepsy and one with cognitive impairment. The diagnosis of CD was confirmed by serologic tests (antiendomysial and antigliadin antibodies) and biopsy of the small intestine. In two patients the neurological symptoms preceded the gastrointestinal abnormalities and in all of them gluten restriction failed to improve the neurological disability. Conclusion: CD should be ruled out in the differential diagnosis of neurological dysfunction of unknown cause, including ataxia, epilepsy and dementia. A gluten free diet, the mainstay of treatment, failed to improve the neurological disability.

KEY WORDS: celiac disease, cerebellar ataxia, epilepsy, cognitive impairment.

Celiac disease (CD) is an autoimmune disease of the small intestine precipitated by the ingestion of gluten in genetically susceptible individuals. The true prevalence is difficult to ascertain since many patients have atypical symptoms. Studies in both Europe and North America estimate the seroprevalence to be 1 of every 120 to 300 persons¹². The symptoms of CD may appear with the introduction of cereals in an infant's diet or may first become evident in adulthood. Classic signs are related to the gastrointestinal tract. Extraintestinal manifestations include anemia, coagulopathy, metabolic bone diseases, infertility³, psychiatric syndromes³ and various neurological disorders³. The diagnosis of CD is based on serologic tests (antiendomysial, antigliadin and antitransglutaminase antibodies) and on characteristic histopathological changes (villous atrophy, crypt hyperplasia and inflammatory-cell infiltrates) seen on distal duodenal biopsy, the gold standard test. Initiation of a gluten-free diet rapidly reverses the mucosal lesion and corrects malabsorption with symptomatic improvement⁴⁵.
Neurological complications are estimated to occur in 6 to 10% of patients with CD. Recently a high proportion of patients with neurological symptoms of unknown origin were found to have gluten sensitivity. Cerebellar ataxia, epilepsy, neuropathy, dementia and multifocal leukoencephalopathy have all been described. Only exceptionally these syndromes improved with gluten restriction, and, in some patients, the neurological manifestations even progress despite resolution of both pathologic findings and intestinal symptoms.

We report three cases of patients with predominant neurological symptoms who had a diagnosis of previously unsuspected CD.

**CASES**

Case 1 – A 40-year-old woman was admitted to the hospital because of severe intention tremor and gait disorder that started four years ago. Routine blood examination revealed only a microcytic anemia and decreased ceruloplasmin levels. Computed tomographic scan of the brain was normal. The patient was treated with penicillamine for Wilson’s disease. One year later, myoclonus and dysarthria occurred. Some weeks afterwards, the patient presented diarrhea and important weight loss. The laboratory findings showed a slight reduction of serum vitamin E, B12 and folic acid. Ceruloplasmin level was normal. Tests for antiendomysium and IgA antigliadin were negative, but IgG antigliadin was highly positive. Sudam III and xylose tests showed malabsorption. A small intestine biopsy demonstrated the classic histological lesion of untreated CD (villous atrophy, crypt hyperplasia and inflammatory-cell infiltrates). The patient was placed on a gluten-free diet with improvement of the gastrointestinal symptoms. In the following year, intention tremor, ataxic gait, myoclonus and dysarthria were associated with terminal dysmetria, inferior limbs paresis and incoordination. Magnetic resonance imaging (MRI) of the brain demonstrated marked cerebellar atrophy. Despite the normalization of vitamin levels, the patient remains with neurological symptoms.

Case 2 – A 24-year-old woman was first seen in 1999 for epilepsy. She had had complex-partial crises for one year. Her physical and neurological examinations were unremarkable at that time. A MRI showed multiple white matter hyperintensities on T2-weighted images and a left frontal lesion that enhanced after gadolinium administration. She was treated for neurocysticercosis based on serologic and cerebrospinal fluid reactions. Oxcarbazepine was initiated. One year later, she developed inattention, learning difficulties and postural tremors. At that time, she was using divalproate sodium because of intolerance to oxcarbazepine. A MRI was repeated and showed a cicatricial left frontal lesion and the same white matter abnormalities. Topiramate was substituted for divalproate and the tremor and cognitive symptoms improved, but did not resolve. She started loosing weight progressively and did not improve after discontinuing topiramate. At that time, tests for antigliadin antibody were highly positive and a small intestine biopsy showed important villous atrophy. She gained weight with a gluten-free diet. One year later, she discontinued the diet and persisted with mild cognitive symptoms, but did not have epileptic crises again.

Case 3 – A 45-year-old man was first seen in 2001 because of memory loss and inability to work for one year. His neurological examination was unremarkable except for a mini-mental examination (MME) of 22, an important delay in answering simple questions and difficulty in naming objects. He had a previous history of chronic diarrhea that was never investigated. A high titer of antiendomysium antibody was detected and a small bowel biopsy showed inflammatory changes. Neurocognitive evaluation revealed inattention, evocation deficits, impaired verbal fluency and disturbed visual and verbal memories. A brain MRI showed cortical and cerebellar atrophy (Fig 1). He was placed on a gluten-free diet and gastrointestinal symptoms resolved, but he persisted with an important cognitive impairment. Eighteen months later a new neuropsychological evaluation showed progression of the deficits. The patient is now stable with a new brain MRI similar to the previous one and a MME of 25 obtained in his last visit.

**DISCUSSION**

Neurological disorders associated with gastrointestinal (GI), pancreatic, or liver diseases are poor-
ly recognized. In consequence, their diagnosis and treatment are often unnecessarily delayed. Malabsorption is a word used to describe disorders in which ingested nutrients are not completely absorbed. These conditions can cause neurological abnormalities both through specific nutritional deficiencies and through multisystem involvement associated with specific disorders. The differential diagnosis of mucosal malabsorption disorders is quite broad and include: CD, nongranulomatous ulcerative jejunoileitis, eosinophilic gastroenteritis, Crohn’s disease, radiation enteritis, immunoproliferative small intestinal disease and chronic mesenteric ischemia.

CD may present with numerical neurological manifestations even without clinical evident malabsorption of nutrients. Although neurological symptoms are rare in children, as many as 36 percent of adult patients have been reported to have neurological manifestations. Cerebellar ataxia, dementia and myositis may involve the central nervous system manifestations of CD. The neuromuscular manifestations of CD include polymyositis, dermatomyositis and inclusion-body myositis.

The diagnostic test for celiac disease is a small intestine biopsy that shows loss of villi and flattening of the mucosa, which is formed of cuboidal cells instead of the normal columnar cells. The crypts are elongated and inflammatory cells may be shown. The screening test for CD is the measurement of circulating antigliadin, antiendomysial and antitransglutaminase antibodies.

It is well known that CD may be associated with sporadic and hereditary ataxias. Our first patient has a six-year history of cerebellar ataxia. Only one year after the presentation of the neurological symptoms, she started to manifest gastrointestinal complaints.

Neuropathologic findings in autopsy of patients with gluten ataxia showed perivascular cuffing with inflammatory cells, predominantly affecting the cerebellum, resulting in loss of Purkinje cells. This suggests that the neurological insult may be immune mediated. Hadjivassiliou et al. showed that in patients with gluten ataxia antigliadin antibodies cross-react with epitopes on Purkinje cells. Recently, it has been suggested that both humoral and cell-mediated responses play a part in the pathogenesis of gluten ataxia. Gluten ataxia is primarily a slowly progressive ataxia, and aggressive cerebellar degeneration is the exception rather than the rule.

Epilepsy is another neurological complication of CD. Many authors described the association of cerebral calcification, CD and seizures. Although various hypotheses have been proposed, ranging from free radical accumulation with oxidative stress to toxicity, the precise mechanisms for such association remains unknown. CD must be considered in selected patients with medically refractory seizures since potential alternative therapies can be helpful. Cross-sectional MRI characteristics have been reported in a few cases of CD associated with neurologic complications. The evolution of cerebral involvement in the course of CD using serial MRIs was described in a case of relapsing-progressive symptoms including brainstem and cerebellar involvement. In this case, the multiple enhancing lesions on the first MRI were favorably modified by steroid treatment, suggesting the presence of an immunologic process.

Our patient had a brain MRI that showed multiple white matter hyperintensities on T2-weighted images and a left frontal lesion that enhanced after gadolinium administration. White matter abnormalities allow differential diagnosis with a wide spectrum of disorders such as: multiple sclerosis, cerebral vasculitis, neurosarcoidosis, Sjögren disease, infectious (Lyme and Whipple) and inherited (adrenoleucodystrophy and metachromatic leukodystrophy) disorders.

Cognitive and psychiatric disturbances were also described in patients with CD. While the burden of any chronic disease is sufficient to cause a mood alteration, studies suggest a distinct profile among patients with CD. Pathophysiology of such clinical signs remains to be determined, but the role of an eventual tissue specific transglutaminase, like in dermatitis herpetiformis, may be suggested. Vitamin B12 deficiency has been associated with hematological, neurological and psychiatric symptoms. Although the terminal ileum is relatively spared in CD, vitamin B12 deficiency is not unusual in untreated CD patients. An immunologic etiology can not be ruled out in patients with CD and cognitive deficits. A study including 33 Alzheimer’s patients and 24 controls showed that the prevalence of CD in Alzheimer’s disease (AD) is not higher than in cognitively unimpaired elders, suggesting that the immune changes in CD are unlikely to play a role in AD.

Antigliadin antibodies have been found in the cerebrospinal fluid in patients with gluten sensitivity and neurological dysfunction. Nevertheless, these antibodies are present in almost all patients...
with CD, but only a small proportion of them develop neurological symptoms. One hypothesis may be that antigliadin antibodies only become neurotoxic if they gain access to the central nervous system.

Our cases demonstrate that neurological symptoms may be the first manifestations of CD and may not respond to or even progress during a gluten-free diet. Accurate diagnosis of CD is challenging because gastrointestinal symptoms may be entirely absent or may be overshadowed by extraintestinal complaints. An increased prevalence of CD has been reported in neurological disorders of unknown etiology. A recent study showed that the frequency of undiagnosed CD might be as high as 16% in patients with neurological manifestations of unknown etiology.

Pathogenic mechanisms of neurological dysfunction in CD remain uncertain. Nowadays, the immune, rather than the nutritional changes of CD, are given more credit in the literature. In fact, neurological symptoms are found with or without histologic evidence of CD, gastrointestinal symptoms or malabsorption signs.

The mucosal lesion and clinical gastrointestinal symptoms recover on gluten-free diet. However, the effect of gluten elimination on neurological manifestations is not very clear. The duration of gluten exposure may be important, but the correlation in a large series was not significant. A long diagnostic delay of CD or poor dietary compliance may be harmful for the overall outcome and lead to severe complications. This report emphasizes the importance of investigating CD in patients with neurological disorders of unknown origin.

REFERENCES